ERBB2 and gastroesophageal junction adenocarcinoma: The ORR in HER2-expressing/mutant non-breast solid tumor patients, including biliary tract cancers, colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma and colorectal cancer, was 45.9%.